Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, potentially causing financial damages to investors [1][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Cytokinetics common stock between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made false statements about the expected FDA approval for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [4]. Group 2: Investor Information - Investors who purchased Cytokinetics stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][5]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].

Accessibility StatementSkip Navigation LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokine ...

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which could impact the company's regulatory approval timeline [1][8]. Allegations - Defendants are accused of making materially false statements about the expected timeline for the NDA submission and approval process for aficamten, claiming FDA approval was anticipated in the second half of 2025 with a PDUFA date of September 26, 2025 [8]. - The company allegedly failed to disclose significant risks, particularly the omission of a required Risk Evaluation and Mitigation Strategy (REMS), which could lead to delays in regulatory approval [8]. Key Dates - Investors must contact the law firm before November 17, 2025, to be eligible for the lead plaintiff motion deadline [4]. Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, with over 125 years of experience in securities litigation, is representing the investors in this case, emphasizing their commitment to justice for those financially harmed by misrepresented statements [5].

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CYTOKINETICS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIAL ...

NEW ORLEANS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) - ...

NEW YORK , Sept. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). ...

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have caused financial losses to shareholders [2]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that Cytokinetics made materially false statements about the expected approval timeline for aficamten, indicating that approval from the U.S. FDA was anticipated in the second half of 2025, based on a PDUFA date of September 26, 2025 [2]. - The company allegedly failed to disclose significant risks related to its inability to submit a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process [2]. - Shareholders experienced financial losses when the truth about the NDA submission was revealed [2]. Group 2: Participation and Representation - Shareholders may be eligible to participate in the class action and those wishing to serve as lead plaintiff must submit their papers by November 17, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [3]. Group 3: Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Cytokinetics, Inc. common stock during the specified Class Period, alleging misleading statements regarding the New Drug Application for aficamten [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Cytokinetics, Inc. and covers stock purchases made between December 27, 2023, and May 6, 2025 [1]. - The lawsuit claims that Cytokinetics made false statements about the expected approval timeline for aficamten, specifically regarding the FDA's approval process and the failure to disclose risks related to the Risk Evaluation and Mitigation Strategy [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting Rosen Law Firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].